Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CHKA | P35790 | 1/20 | 0.36 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.36 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.36 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.35 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22122716 | 0.89 | CA2 (0.42) | KMT2ACA2CA12CA1CA9 | |
| SCHEMBL22672640 | 0.85 | MEN1 (0.40) | KMT2AMEN1CA2CA12CA1 | |
| SCHEMBL22838001 | 0.85 | ALDH1A1 (0.44) | KMT2AMEN1CA2CA12CA1 | |
| SCHEMBL23094386 | 0.85 | POLB (0.44) | KMT2AMEN1CA2CA12CA1 | |
| SCHEMBL22672756 | 0.85 | CA2 (0.36) | KMT2AMEN1CA2CA12CA1 | |
| SCHEMBL28275432 | 0.82 | POLB (0.44) | KMT2ACA2CA12CA1CA9 | |
| SCHEMBL22115271 | 0.82 | CA2 (0.34) | KMT2AMEN1CA2CA12CA1 | |
| SCHEMBL24234390 | 0.82 | POLB (0.36) | KMT2AMEN1CA2CA12CA1 | |
| SCHEMBL20844330 | 0.81 | SMN1; SMN2 (0.38) | KMT2AMEN1CA2CA12CA1 | |
| SCHEMBL15908130 | 0.79 | CYP1A2 (0.39) | KMT2AMEN1POLBLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230193282-A1 | TREATMENT METHODS FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-11642364-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20230045831-A1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | SAREPTA THERAPEUTICS, INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-20230038956-A1 | METHODS FOR TREATING MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20220403385-A1 | COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2022-12-22 | — | — | US | disclosed |
| US-11491238-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-11382981-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11338041-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210338830-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | US | disclosed |
| US-20210220386-A1 | EXON SKIPPING OLIGOMERS AND OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2021-07-22 | — | — | US | disclosed |
| US-20190292208-A1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | SAREPTA THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | US | disclosed |
| US-20190262375-A1 | EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
| US-10364431-B2 | Compositions for treating muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2019-07-30 | — | — | US | disclosed |
| US-20190054113-A1 | METHODS FOR TREATING MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. | 2019-02-21 | — | — | US | disclosed |
| US-20180177814-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-06-28 | — | — | US | disclosed |
| US-20180105811-A1 | COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-04-19 | — | — | US | disclosed |
| US-9682097-B2 | Oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170051278-A1 | METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | SAREPTA THERAPEUTICS, INC. | 2017-02-23 | — | — | US | disclosed |
| EP-2799548-A1 | ANTISENSE NUCLEIC ACID | Nippon Shinyaku Co., Ltd. (JP) | 2014-11-05 | — | — | EP | disclosed |
| US-7264925-B2 | Method for analysis of oligonucleotide analogs | AVI BIOPHARMA, INC. (US) | 2007-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11338041-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SMN1; SMN2, UTRN, RBM17 | KMT2A 3436/4885MEN1 4296/4885CA2 4821/4885 |
| US-20190054113-A1 | METHODS FOR TREATING MUSCULAR DYSTROPHY | UTRN, MTPN, MBNL1 | KMT2A 1118/4885MEN1 4588/4885CA2 4638/4885 |
| US-20230045831-A1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | PPIP5K2, MTAP, RNGTT | KMT2A 3884/4885MEN1 1249/4885CA2 4300/4885 |
| US-20230038956-A1 | METHODS FOR TREATING MUSCULAR DYSTROPHY | UTRN, MTPN, SMN1; SMN2 | KMT2A 2239/4885MEN1 4353/4885CA2 4541/4885 |
| US-11382981-B2 | Exon skipping oligomer conjugates for muscular dystrophy | UTRN, SMN1; SMN2, RBM17 | KMT2A 3664/4885MEN1 4270/4885CA2 4841/4885 |
| US-11642364-B2 | Exon skipping oligomer conjugates for muscular dystrophy | UTRN, SMN1; SMN2, DCLRE1B | KMT2A 3663/4885MEN1 4304/4885CA2 4842/4885 |
| US-20210338830-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | UTRN, SMN1; SMN2, RBM17 | KMT2A 3579/4885MEN1 4336/4885CA2 4827/4885 |
| US-20190292208-A1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | PPIP5K2, MTAP, RNGTT | KMT2A 3884/4885MEN1 1249/4885CA2 4300/4885 |
| US-20210220386-A1 | EXON SKIPPING OLIGOMERS AND OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | UTRN, RBM17, SMN1; SMN2 | KMT2A 3879/4885MEN1 4584/4885CA2 4823/4885 |
| US-11491238-B2 | Exon skipping oligomer conjugates for muscular dystrophy | UTRN, SMN1; SMN2, RBM17 | KMT2A 3489/4885MEN1 4353/4885CA2 4817/4885 |
| US-20180105811-A1 | COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY | MYOF, MTPN, UTRN | KMT2A 3679/4885MEN1 4761/4885CA2 4099/4885 |
| US-20220403385-A1 | COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY | MYOF, MTPN, UTRN | KMT2A 3679/4885MEN1 4761/4885CA2 4099/4885 |
| US-20180177814-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | UTRN, SMN1; SMN2, DCLRE1B | KMT2A 3663/4885MEN1 4304/4885CA2 4842/4885 |
| US-20230193282-A1 | TREATMENT METHODS FOR MUSCULAR DYSTROPHY | MTPN, UTRN, CAPNS1 | KMT2A 2776/4885MEN1 3342/4885CA2 905/4885 |
| US-20170051278-A1 | METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | LMNA, LMNB2, LMNB1 | KMT2A 2685/4885MEN1 1171/4885CA2 4843/4885 |
| US-10364431-B2 | Compositions for treating muscular dystrophy | MYOF, MTPN, UTRN | KMT2A 3679/4885MEN1 4761/4885CA2 4099/4885 |
| US-20190262375-A1 | EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY | RBM17, UTRN, UPF1 | KMT2A 4214/4885MEN1 4539/4885CA2 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.